Clinical Trials Logo

Philadelphia-Negative ALL clinical trials

View clinical trials related to Philadelphia-Negative ALL.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06287528 Recruiting - Clinical trials for Refractory Acute Lymphoblastic Leukemia

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Start date: February 23, 2024
Phase: Phase 1
Study type: Interventional

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' study therapy will take about 2-4 weeks.

NCT ID: NCT06250959 Recruiting - ALL, Adult Clinical Trials

RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.

BEAT-ALL-2024
Start date: February 5, 2024
Phase: Phase 2
Study type: Interventional

In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated.

NCT ID: NCT04334993 Recruiting - High-Risk Cancer Clinical Trials

Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

Despite recent therapeutic advancements, the outcome of young adults with Philadelphia-negative (Ph-neg) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) remains unsatisfactory, especially in those patients with high-risk disease features. In young adults pediatric-based chemotherapy approaches improve outcome. Furthermore, there is evidence that pre-transplant antibody-based therapy may render patients with positive minimal residual disease (MRD+) to an MRD-negative status (MRD-) and that this may be associated with improved post-transplant outcome. This is prospective study to evaluate the potential benefit of a modified pediatric-based approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant antibody-based consolidation in high-risk patients with Ph-neg ALL will be performed.